Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Spruce Biosciences (Nasdaq: SPRB), a biopharmaceutical company, announced that CEO Richard King will participate in a virtual fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 PM EDT. Interested parties can access the live webcast through the company's investor relations website and an archived replay will be available for 30 days post-event. Spruce is focused on developing therapies for rare endocrine disorders, including its product candidate tildacerfont, aimed at treating classic congenital adrenal hyperplasia and a specific form of polycystic ovary syndrome.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Richard King, Chief Executive Officer, will participate in a virtual fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021 at 5:25pm EDT.

Interested parties can access the live webcast for the conference from the Events section of the company’s investor relations website at https://investors.sprucebiosciences.com. An archived replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS (estimated to be 150,000 to 200,000 patients in the United States). To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005039/en/

FAQ

When is Richard King speaking at the RBC Capital Markets Global Healthcare Conference?

Richard King will participate in the fireside chat on May 19, 2021, at 5:25 PM EDT.

How can I access the live webcast for the RBC Capital Markets Global Healthcare Conference?

The live webcast can be accessed on the Events section of Spruce Biosciences' investor relations website.

What is tildacerfont being developed for by Spruce Biosciences?

Tildacerfont is being developed as a non-steroidal therapy for classic congenital adrenal hyperplasia and a rare form of polycystic ovary syndrome.

What are the estimated patient numbers for the conditions Spruce is targeting?

Approximately 150,000 to 200,000 patients in the U.S. suffer from the rare form of polycystic ovary syndrome with primary adrenal androgen excess.

How long will the archived replay of the RBC Capital Markets Global Healthcare Conference be available?

The archived replay will be accessible for approximately 30 days after the live presentation.